Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025
Standard BioTools (NASDAQ:LAB) has scheduled its second quarter 2025 earnings conference call for August 11, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and operational progress.
Investors can join via phone using the following dial-in numbers: (888) 346-3970 for US domestic callers and (412) 902-4297 for international callers. The webcast will be accessible through the company's Investor Relations page and will be archived at investors.standardbio.com.
Standard BioTools (NASDAQ:LAB) ha programmato la conferenza telefonica per la presentazione dei risultati del secondo trimestre 2025 per il 11 agosto 2025, dopo la chiusura del mercato. L'azienda terrà una conference call e una trasmissione web alle 16:30 ET per discutere i risultati finanziari e i progressi operativi.
Gli investitori possono partecipare telefonicamente utilizzando i seguenti numeri: (888) 346-3970 per chiamate interne agli USA e (412) 902-4297 per chiamate internazionali. La trasmissione web sarà disponibile tramite la pagina Investor Relations della società e resterà archiviata su investors.standardbio.com.
Standard BioTools (NASDAQ:LAB) ha programado su llamada de conferencia de resultados para el segundo trimestre de 2025 el 11 de agosto de 2025, después del cierre del mercado. La empresa realizará una llamada y una transmisión en vivo a las 4:30 p.m. ET para discutir los resultados financieros y el progreso operativo.
Los inversores pueden unirse por teléfono utilizando los siguientes números: (888) 346-3970 para llamadas nacionales en EE.UU. y (412) 902-4297 para llamadas internacionales. La transmisión estará disponible a través de la página de Relaciones con Inversionistas de la compañía y quedará archivada en investors.standardbio.com.
Standard BioTools (NASDAQ:LAB)는 2025년 2분기 실적 컨퍼런스 콜을 2025년 8월 11일 장 마감 후에 예정했습니다. 회사는 재무 성과 및 운영 진행 상황을 논의하기 위해 오후 4시 30분(동부 시간)에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
투자자들은 미국 내 전화는 (888) 346-3970, 국제 전화는 (412) 902-4297 번호로 참여할 수 있습니다. 웹캐스트는 회사 투자자 관계 페이지에서 접속 가능하며 investors.standardbio.com에 아카이브됩니다.
Standard BioTools (NASDAQ:LAB) a programmé sa conférence téléphonique sur les résultats du deuxième trimestre 2025 pour le 11 août 2025, après la clôture du marché. La société organisera une conférence téléphonique et une webdiffusion à 16h30 ET pour discuter des résultats financiers et des avancées opérationnelles.
Les investisseurs peuvent participer par téléphone en utilisant les numéros suivants : (888) 346-3970 pour les appels nationaux aux États-Unis et (412) 902-4297 pour les appels internationaux. La webdiffusion sera accessible via la page Relations Investisseurs de la société et sera archivée sur investors.standardbio.com.
Standard BioTools (NASDAQ:LAB) hat seine Telefonkonferenz zur Bekanntgabe der Ergebnisse für das zweite Quartal 2025 für den 11. August 2025 nach Börsenschluss angesetzt. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse und den operativen Fortschritt zu besprechen.
Investoren können telefonisch über folgende Nummern teilnehmen: (888) 346-3970 für Anrufer aus den USA und (412) 902-4297 für internationale Anrufer. Der Webcast ist über die Investor-Relations-Seite des Unternehmens zugänglich und wird auf investors.standardbio.com archiviert.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.
Individuals can access the conference call by dialing:
US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297
Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2025 Standard BioTools Inc. All rights reserved.
Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Investor Contact:
Marissa Bych
ir@standardbio.com
FAQ
When is Standard BioTools (LAB) reporting Q2 2025 earnings?
What time is Standard BioTools Q2 2025 earnings call?
How can I access Standard BioTools (LAB) Q2 2025 earnings call?
Where can I find the replay of Standard BioTools Q2 earnings webcast?
